Hematological Malignancies

Rituximab maintenance vs observation in relapsed FL (EORTC 20981): PFS

0 20 40 60 80 100

PFS increase > 2.4 years

Rituximab maintenance median 3.7 years

PFS (%)

Observation median 1.3 years

HR = 0.55 p < 0.0001

0

1

2

3

4

5

6

7

8

Time (years)

van Oers MHJ, et al. J Clin Oncol 2010; 28:2853–2858.